Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907175097> ?p ?o ?g. }
- W2907175097 endingPage "477" @default.
- W2907175097 startingPage "470" @default.
- W2907175097 abstract "To investigate the relationship between the expression of linc-VLDLR in extracellular vesicles (EVs) and esophageal carcinomas development and drug resistance. The expression of linc-VLDLR and ABCG2 mRNA in 60 cases of esophageal carcinoma tissue, para-carcinoma tissue and the normal esophagus tissue were detected using Fluorescence quantitative reverse transcription polymerase chain reaction (qRT-PCR). Fifty percent inhibiting concentration (IC50) of adriamycin (ADM) to Eca109 cells was detected by MTT assay, after the treatment of different concentrations of adriamycin (ADM) on esophageal squamous cell carcinoma Eca109 cell line for 24 h. EVs were extracted from culture medium after the treatment of three concentrations of ADM (setting based on the IC50) on Eca109 cells for 24 h. Linc-VLDLR expression in EVs was detected by qRT-PCR. After the treatment of the extracted EVs on virgin Eca109 cells for 48 h, then intervening these cells for 24 h by different concentrations of ADM, the new values of IC50 were detected by MTT assay. Cell cycle, cell apoptosis and ABCG2 protein expression of these Eca109 cells were detected by flow cytometry (FCM). Linc-VLDLR and ABCG2 mRNA expression in these Eca109 cells were detected by qRT-PCR. Expression of linc-VLDLR and ABCG2 mRNA in esophageal squamous cell carcinoma tissue were significantly higher than that in esophageal atypical hyperplasia and normal esophagus tissue, P < 0.01. After the treatment of ADM on Eca109 cells for 24 h, IC50 of Eca109 cells was detected as (0.44 ± 0.02) μg/mL, thus ADM concentrations of 0, 0.2, 0.4 and 0.8 μg/mL were selected to accomplish the following parts of this study. After four groups of Eca109 cells were treated by ADM in different concentrations separately, extracted EVs from the supernatant of all four groups, then labeling these four groups as EVs1, 2, 3 and 4. Linc-VLDLR expression in EVs4 was significantly higher than that in EVs1-3, P < 0.01. After the treatment of EVs1-4 on virgin Eca109 cells for 48 h, new values of IC50 of Eca109 to ADM were detected by MTT. It was found that the IC50 value of group EVs4 was significantly higher than that of other groups, P < 0.05. Flow cytometry results showed that the proliferation index of Eca109 cells in EVs4 was significantly higher than that in EVs1-3 and control groups, P < 0.01. Whereas, there was an obviously downward trend in the apoptosis rate of EVs4, compared to other three groups, P < 0.01. Linc-VLDLR and ABCG2 mRNA and protein expression level in Eca109 cells of EVs4 group were significantly higher than that of EVs1-3 and control groups, P < 0.05. High expression of Linc-VLDLR and ABCG2 gene in esophageal cancer cells affected the formation of esophageal cancer drug resistance. EVs released by drug-resistant cells were proved that they could upregulate the expression of ABCG2 in esophageal cancer cells and thus regulate the drug resistance of esophageal cancer cells, which was related to the linc-VLDLR carried by EVs." @default.
- W2907175097 created "2019-01-11" @default.
- W2907175097 creator A5006833609 @default.
- W2907175097 creator A5024406300 @default.
- W2907175097 creator A5031252469 @default.
- W2907175097 creator A5037677450 @default.
- W2907175097 creator A5068252474 @default.
- W2907175097 creator A5076277725 @default.
- W2907175097 date "2019-03-01" @default.
- W2907175097 modified "2023-09-30" @default.
- W2907175097 title "Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells" @default.
- W2907175097 cites W1488814076 @default.
- W2907175097 cites W1566169834 @default.
- W2907175097 cites W1587942505 @default.
- W2907175097 cites W1765254582 @default.
- W2907175097 cites W1965765543 @default.
- W2907175097 cites W1991953785 @default.
- W2907175097 cites W1999204959 @default.
- W2907175097 cites W2015500738 @default.
- W2907175097 cites W2038974826 @default.
- W2907175097 cites W2045521934 @default.
- W2907175097 cites W2099526120 @default.
- W2907175097 cites W2099567806 @default.
- W2907175097 cites W2110964883 @default.
- W2907175097 cites W2120755527 @default.
- W2907175097 cites W2121354606 @default.
- W2907175097 cites W2148167937 @default.
- W2907175097 cites W2159533261 @default.
- W2907175097 cites W2165275858 @default.
- W2907175097 cites W2405954739 @default.
- W2907175097 cites W2529378193 @default.
- W2907175097 cites W2568741610 @default.
- W2907175097 cites W2587850954 @default.
- W2907175097 cites W2588307382 @default.
- W2907175097 cites W2593773150 @default.
- W2907175097 cites W2725777854 @default.
- W2907175097 cites W38091031 @default.
- W2907175097 cites W4255548056 @default.
- W2907175097 doi "https://doi.org/10.1016/j.prp.2018.12.033" @default.
- W2907175097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30606658" @default.
- W2907175097 hasPublicationYear "2019" @default.
- W2907175097 type Work @default.
- W2907175097 sameAs 2907175097 @default.
- W2907175097 citedByCount "27" @default.
- W2907175097 countsByYear W29071750972019 @default.
- W2907175097 countsByYear W29071750972020 @default.
- W2907175097 countsByYear W29071750972021 @default.
- W2907175097 countsByYear W29071750972022 @default.
- W2907175097 countsByYear W29071750972023 @default.
- W2907175097 crossrefType "journal-article" @default.
- W2907175097 hasAuthorship W2907175097A5006833609 @default.
- W2907175097 hasAuthorship W2907175097A5024406300 @default.
- W2907175097 hasAuthorship W2907175097A5031252469 @default.
- W2907175097 hasAuthorship W2907175097A5037677450 @default.
- W2907175097 hasAuthorship W2907175097A5068252474 @default.
- W2907175097 hasAuthorship W2907175097A5076277725 @default.
- W2907175097 hasConcept C121608353 @default.
- W2907175097 hasConcept C133936738 @default.
- W2907175097 hasConcept C142724271 @default.
- W2907175097 hasConcept C1491633281 @default.
- W2907175097 hasConcept C153911025 @default.
- W2907175097 hasConcept C185592680 @default.
- W2907175097 hasConcept C190283241 @default.
- W2907175097 hasConcept C2777546739 @default.
- W2907175097 hasConcept C2779742542 @default.
- W2907175097 hasConcept C2780783641 @default.
- W2907175097 hasConcept C29537977 @default.
- W2907175097 hasConcept C501593827 @default.
- W2907175097 hasConcept C502942594 @default.
- W2907175097 hasConcept C54355233 @default.
- W2907175097 hasConcept C553184892 @default.
- W2907175097 hasConcept C55493867 @default.
- W2907175097 hasConcept C71924100 @default.
- W2907175097 hasConcept C81885089 @default.
- W2907175097 hasConcept C86803240 @default.
- W2907175097 hasConceptScore W2907175097C121608353 @default.
- W2907175097 hasConceptScore W2907175097C133936738 @default.
- W2907175097 hasConceptScore W2907175097C142724271 @default.
- W2907175097 hasConceptScore W2907175097C1491633281 @default.
- W2907175097 hasConceptScore W2907175097C153911025 @default.
- W2907175097 hasConceptScore W2907175097C185592680 @default.
- W2907175097 hasConceptScore W2907175097C190283241 @default.
- W2907175097 hasConceptScore W2907175097C2777546739 @default.
- W2907175097 hasConceptScore W2907175097C2779742542 @default.
- W2907175097 hasConceptScore W2907175097C2780783641 @default.
- W2907175097 hasConceptScore W2907175097C29537977 @default.
- W2907175097 hasConceptScore W2907175097C501593827 @default.
- W2907175097 hasConceptScore W2907175097C502942594 @default.
- W2907175097 hasConceptScore W2907175097C54355233 @default.
- W2907175097 hasConceptScore W2907175097C553184892 @default.
- W2907175097 hasConceptScore W2907175097C55493867 @default.
- W2907175097 hasConceptScore W2907175097C71924100 @default.
- W2907175097 hasConceptScore W2907175097C81885089 @default.
- W2907175097 hasConceptScore W2907175097C86803240 @default.
- W2907175097 hasFunder F4320322163 @default.
- W2907175097 hasIssue "3" @default.
- W2907175097 hasLocation W29071750971 @default.
- W2907175097 hasLocation W29071750972 @default.